Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) insider Kate Mckinley bought 17,960 shares of the stock in a transaction that occurred on Friday, December 13th. The shares were purchased at an average cost of $1.67 per share, with a total value of $29,993.20. Following the purchase, the insider now directly owns 17,960 shares of the company's stock, valued at $29,993.20. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.
Rani Therapeutics Stock Down 4.2 %
Shares of NASDAQ RANI opened at $1.59 on Tuesday. The company has a quick ratio of 1.60, a current ratio of 1.60 and a debt-to-equity ratio of 2.34. The firm has a market cap of $91.09 million, a PE ratio of -1.50 and a beta of 0.05. The company's fifty day simple moving average is $2.22 and its 200 day simple moving average is $2.82. Rani Therapeutics Holdings, Inc. has a 12-month low of $1.58 and a 12-month high of $8.75.
Hedge Funds Weigh In On Rani Therapeutics
Several institutional investors have recently made changes to their positions in RANI. Stifel Financial Corp grew its stake in shares of Rani Therapeutics by 100.4% in the 3rd quarter. Stifel Financial Corp now owns 269,768 shares of the company's stock valued at $583,000 after buying an additional 135,148 shares during the period. King Luther Capital Management Corp grew its stake in Rani Therapeutics by 44.5% in the third quarter. King Luther Capital Management Corp now owns 81,129 shares of the company's stock valued at $175,000 after acquiring an additional 25,000 shares during the period. Geode Capital Management LLC increased its holdings in shares of Rani Therapeutics by 14.3% during the third quarter. Geode Capital Management LLC now owns 172,261 shares of the company's stock valued at $372,000 after acquiring an additional 21,527 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Rani Therapeutics during the second quarter worth approximately $81,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Rani Therapeutics by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 685,303 shares of the company's stock worth $2,131,000 after purchasing an additional 16,956 shares in the last quarter. Institutional investors and hedge funds own 30.19% of the company's stock.
Wall Street Analyst Weigh In
AI breakthrough about to upend industry
From Porter & Company | Ad
Everyone is talking about AI right now.
The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI.
But here’s the thing.
I urge you to watch it now.
Separately, HC Wainwright reiterated a "buy" rating and set a $9.00 price target on shares of Rani Therapeutics in a report on Tuesday, November 19th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $11.71.
Get Our Latest Report on Rani Therapeutics
Rani Therapeutics Company Profile
(
Get Free Report)
Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
